Current Antimalarial Therapies and Advances in the Development of Semi-Synthetic Artemisinin Derivatives
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Trypanocidal Activity of Ethanolic Leaf Extract of Andrographis Paniculata
Science World Journal Vol. 15(No 4) 2020 www.scienceworldjournal.org ISSN: 1597-6343 (Online), ISSN: 2756-391X (Print) Published by Faculty of Science, Kaduna State University TRYPANOCIDAL ACTIVITY OF ETHANOLIC LEAF EXTRACT OF ANDROGRAPHIS PANICULATA 1* 2 3 4 Ladan Z., Olanrewaju T. O., Maikaje D.B., and Waziri P. N. Full Length Research Article 1Department of Chemistry, Kaduna State University, Kaduna, Nigeria 2Human African Trypanosomiasis Research Department, Nigerian Institute for Trypanosomiasis Research, Kaduna, Nigeria 3Department of Microbiology, Kaduna State University, Kaduna, Nigeria 4Department of Biochemistry, Kaduna State University, Kaduna, Nigeria *Corresponding Author’s Email Address: [email protected] Phone: 2347030475898 ABSTRACT animal Trypanosomiasis (Achenef and Bekele, 2013; Giordani et Andrographis paniculata used in this study belongs to Acanthacae al., 2016). Various industries are now on the search for sources of family and is commonly known as king of bitters. This study aimed alternative which include synthetic and natural products. Medicinal at evaluating effect of A. paniculata leaf extract on experimental plants remain a major source of alternative medicine and scientific rats infected with Trypanosoma brucei brucei. Cold maceration was investigations have shown that various plants indicate promising used for extraction and the biomass was fractionated in open results for the development of cheaper less toxic drugs for column chromatography. One of the ethanolic fractions obtained treatment and management of trypanosomiasis (Simoben et al., from A. paniculata was evaluated for in vitro and in vivo activities 2018). Andrographis paniculata evaluated in this study belong to using RPMI 1640 cell culture media and experimental wistar rats Acanthacae family of the plant kingdom and commonly known as respectively. -
Eurartesim, INN-Piperaquine & INN-Artenimol
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Eurartesim 160 mg/20 mg film-coated tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 160 mg piperaquine tetraphosphate (as the tetrahydrate; PQP) and 20 mg artenimol. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). White oblong biconvex film-coated tablet (dimension 11.5x5.5mm / thickness 4.4mm) with a break-line and marked on one side with the letters “S” and “T”. The tablet can be divided into equal doses. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Eurartesim is indicated for the treatment of uncomplicated Plasmodium falciparum malaria in adults, adolescents, children and infants 6 months and over and weighing 5 kg or more. Consideration should be given to official guidance on the appropriate use of antimalarial medicinal products, including information on the prevalence of resistance to artenimol/piperaquine in the geographical region where the infection was acquired (see section 4.4). 4.2 Posology and method of administration Posology Eurartesim should be administered over three consecutive days for a total of three doses taken at the same time each day. 2 Dosing should be based on body weight as shown in the table below. Body weight Daily dose (mg) Tablet strength and number of tablets per dose (kg) PQP Artenimol 5 to <7 80 10 ½ x 160 mg / 20 mg tablet 7 to <13 160 20 1 x 160 mg / 20 mg tablet 13 to <24 320 40 1 x 320 mg / 40 mg tablet 24 to <36 640 80 2 x 320 mg / 40 mg tablets 36 to <75 960 120 3 x 320 mg / 40 mg tablets > 75* 1,280 160 4 x 320 mg / 40 mg tablets * see section 5.1 If a patient vomits within 30 minutes of taking Eurartesim, the whole dose should be re-administered; if a patient vomits within 30-60 minutes, half the dose should be re-administered. -
Pharmacological and Cardiovascular Perspectives on the Treatment of COVID-19 with Chloroquine Derivatives
www.nature.com/aps REVIEW ARTICLE Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives Xiao-lei Zhang1, Zhuo-ming Li1, Jian-tao Ye1, Jing Lu1, Lingyu Linda Ye2, Chun-xiang Zhang3, Pei-qing Liu1 and Dayue D Duan2 The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) and an ongoing severe pandemic. Curative drugs specific for COVID-19 are currently lacking. Chloroquine phosphate and its derivative hydroxychloroquine, which have been used in the treatment and prevention of malaria and autoimmune diseases for decades, were found to inhibit SARS-CoV-2 infection with high potency in vitro and have shown clinical and virologic benefits in COVID-19 patients. Therefore, chloroquine phosphate was first used in the treatment of COVID-19 in China. Later, under a limited emergency- use authorization from the FDA, hydroxychloroquine in combination with azithromycin was used to treat COVID-19 patients in the USA, although the mechanisms of the anti-COVID-19 effects remain unclear. Preliminary outcomes from clinical trials in several countries have generated controversial results. The desperation to control the pandemic overrode the concerns regarding the serious adverse effects of chloroquine derivatives and combination drugs, including lethal arrhythmias and cardiomyopathy. The risks of these treatments have become more complex as a result of findings that COVID-19 is actually a multisystem disease. While respiratory symptoms are the major clinical manifestations, cardiovascular abnormalities, including arrhythmias, myocarditis, heart failure, and ischemic stroke, have been reported in a significant number of COVID-19 patients. Patients with preexisting cardiovascular conditions (hypertension, arrhythmias, etc.) are at increased risk of severe COVID-19 and death. -
Pyronaridine Was Effective and Well Tolerated in African Patients with Acute, Uncomplicated Falcipamm Malaria
Evid Based Med: first published as 10.1136/ebm.1996.1.150 on 1 August 1996. Downloaded from Pyronaridine was effective and well tolerated in African patients with acute, uncomplicated falcipamm malaria RingwaldP, BickiiJ, Basco L. Random- symptoms of severe and complicated chloroquine) to have 1 additional treat- ised trial of pyronaridine versus malaria, recent self-medication, preg- ment success, 95% CI2 to 4; the rela- chloroquine for acute uncomplicated nancy, or mixed malaria infections. 81 tive risk improvement (RBI) was 71%, fakiparum malaria in Africa. Lancet. patients (84%) were included in the CI 36% to 128%.}* Pyronaridine led 1996 Jan 6;341:24~8. on-active-treatment analysis. to 100% parasite clearance by day 14 compared with 44% clearance in the intervention chloroquine group (? < 0.001) {ARI Objective 41 patients were allocated to 25 rag/kg 56%; NNT 2, CI 1 to 2; RRI128%, To compare the effectiveness of oral of chloroquine, and 40 patients were CI 69% to 231%}*. No significant dif- pyronaridine with chloroquine for allocated to 32 mg/kg of pyronari- ferences occurred in the fever- or para- acute, uncomplicated falciparum ma- dine; both treatments were given site-clearance times between patients laria in African adults. orally in divided doses for 3 days. Pa- with favourable responses in the pyro- Design tients were followed for 14 days on an naridine group and diose with favour- Randomised controlled trial with outpatient basis. able responses in the chloroquine 14-day follow-up. group. Mild gastrointestinal symptoms Main outcome measures were common with pyronaridine, but Treatment success at day 14 (defined Setting no serious adverse effects were noted. -
Pyramax, See the Summary of Product Characteristics (Smpc)
EMA/3102/2016 EMEA/H/W/002319 EPAR summary for the public Pyramax pyronaridine tetraphosphate / artesunate This is a summary of the European public assessment report (EPAR) for Pyramax. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion on the medicine and its recommendations on the conditions of use for Pyramax. What is Pyramax? Pyramax is a medicine that contains the active substances pyronaridine tetraphosphate and artesunate. It is available as tablets (180 mg/60 mg) and as granules (60 mg/20 mg in each sachet). What is Pyramax used for? Pyramax is used to treat uncomplicated malaria, caused by two types of malaria parasites, Plasmodium falciparum and Plasmodium vivax. ‘Uncomplicated’ means the disease does not involve severe, life- threatening symptoms. Pyramax tablets are used for adults and children weighing 20 kg or more and the granules are used for babies and children weighing between 5 and 20 kg. The medicine can only be obtained with a prescription. How is Pyramax used? Pyramax is taken once a day for three days. The daily dose depends on the patient’s weight, and for tablets it ranges from one tablet a day for patients weighing between 20 and 24 kg to four tablets a day for patients over 65 kg. Pyramax granules suspended in water are used for babies and children weighing from 5 kg to under 20 kg. The dose ranges from one sachet a day for babies and children weighing between 5 and under 8 kg to three sachets a day for children weighing between 15 and under 20 kg. -
Plasmodium Falciparum Clinical Isolates: in Vitro Genotypic and Phenotypic Characterization Nonlawat Boonyalai1* , Brian A
Boonyalai et al. Malar J (2020) 19:269 https://doi.org/10.1186/s12936-020-03339-w Malaria Journal RESEARCH Open Access Piperaquine resistant Cambodian Plasmodium falciparum clinical isolates: in vitro genotypic and phenotypic characterization Nonlawat Boonyalai1* , Brian A. Vesely1, Chatchadaporn Thamnurak1, Chantida Praditpol1, Watcharintorn Fagnark1, Kirakarn Kirativanich1, Piyaporn Saingam1, Chaiyaporn Chaisatit1, Paphavee Lertsethtakarn1, Panita Gosi1, Worachet Kuntawunginn1, Pattaraporn Vanachayangkul1, Michele D. Spring1, Mark M. Fukuda1, Chanthap Lon1, Philip L. Smith2, Norman C. Waters1, David L. Saunders3 and Mariusz Wojnarski1 Abstract Background: High rates of dihydroartemisinin–piperaquine (DHA–PPQ) treatment failures have been documented for uncomplicated Plasmodium falciparum in Cambodia. The genetic markers plasmepsin 2 (pfpm2), exonuclease (pfexo) and chloroquine resistance transporter (pfcrt) genes are associated with PPQ resistance and are used for moni- toring the prevalence of drug resistance and guiding malaria drug treatment policy. Methods: To examine the relative contribution of each marker to PPQ resistance, in vitro culture and the PPQ survival assay were performed on seventeen P. falciparum isolates from northern Cambodia, and the presence of E415G-Exo and pfcrt mutations (T93S, H97Y, F145I, I218F, M343L, C350R, and G353V) as well as pfpm2 copy number polymor- phisms were determined. Parasites were then cloned by limiting dilution and the cloned parasites were tested for drug susceptibility. Isobolographic analysis of several drug combinations for standard clones and newly cloned P. falciparum Cambodian isolates was also determined. Results: The characterization of culture-adapted isolates revealed that the presence of novel pfcrt mutations (T93S, H97Y, F145I, and I218F) with E415G-Exo mutation can confer PPQ-resistance, in the absence of pfpm2 amplifcation. -
Pharmaceutical Composition Comprising Artesunate
(19) TZZ ¥ 4B_T (11) EP 2 322 244 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61P 33/06 (2006.01) A61K 9/20 (2006.01) 21.11.2012 Bulletin 2012/47 A61K 31/357 (2006.01) A61K 31/505 (2006.01) A61K 31/4965 (2006.01) (21) Application number: 10192206.0 (22) Date of filing: 09.09.2005 (54) Pharmaceutical composition comprising artesunate, sulfamethoxypyrazine and pyrimethamine suitable for the treatment of malaria within one day, in the form of a tablet Pharmazeutische Zusammensetzung enthaltend Artesunat, Sulfamethoxypyrazin und Pyrimethamin, die zur Behandlung von Malaria innerhalb eines Tages geeignet ist, in Form einer Tablette Composition pharmaceutique à base d’artesunate, de sulfaméthoxypyrazine et de pyriméthamine permettant le traitement du palludisme en un jour, sous forme de comprimé (84) Designated Contracting States: (56) References cited: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • LUXEMBURGER C ET AL: "Single day HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI mefloquine-artesunate combination in the SK TR treatment of multi-drug resistant falciparum malaria", TRANSACTIONS OF THE ROYAL (43) Date of publication of application: SOCIETY OF TROPICAL MEDICINE AND 18.05.2011 Bulletin 2011/20 HYGIENE, ELSEVIER, GB, vol. 88, no. 2, 1 March 1994 (1994-03-01), pages 213-217, XP023097868, (62) Document number(s) of the earlier application(s) in ELSEVIER, GB ISSN: 0035-9203, DOI: accordance with Art. 76 EPC: 10.1016/0035-9203(94)90303-4 [retrieved on 05795966.0 / 1 940 519 1994-03-01] • DAO ET AL: "Fatty food does not alter blood (73) Proprietor: Dafra Pharma N.V. -
Artemether-Lumefantrine (Six-Dose Regimen) for Treating Uncomplicated Falciparum Malaria (Review)
Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria (Review) Omari AAA, Gamble CL, Garner P This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2009, Issue 1 http://www.thecochranelibrary.com Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 3 METHODS ...................................... 3 RESULTS....................................... 5 DISCUSSION ..................................... 9 AUTHORS’CONCLUSIONS . 9 ACKNOWLEDGEMENTS . 10 REFERENCES ..................................... 10 CHARACTERISTICSOFSTUDIES . 13 DATAANDANALYSES. 20 Analysis 1.1. Comparison 1 Artemether-lumefantrine vs amodiaquine, Outcome 1 Total failure by day 28. 22 Analysis 1.2. Comparison 1 Artemether-lumefantrine vs amodiaquine, Outcome 2 Total failure by day 14. 23 Analysis 1.3. Comparison 1 Artemether-lumefantrine vs amodiaquine, Outcome 3 Gametocyte carriage on day 14. 23 Analysis 2.1. Comparison 2 Artemether-lumefantrine vs chloroquine plus sulfadoxine-pyrimethamine, Outcome 1 Total failurebyday28. ................................ 24 Analysis 2.2. Comparison 2 Artemether-lumefantrine -
Dihydropteroate Synthase Gene Mutations in Pneumocystis
Dihydropteroate Synthase Gene Mutations in Pneumocystis and Sulfa Resistance Laurence Huang,* Kristina Crothers,* Chiara Atzori,† Thomas Benfield,‡ Robert Miller,§ Meja Rabodonirina,¶ and Jannik Helweg-Larsen# Pneumocystis pneumonia (PCP) remains a major Patients who are not receiving regular medical care, as cause of illness and death in HIV-infected persons. Sulfa well as those who are not receiving or responding to anti- drugs, trimethoprim-sulfamethoxazole (TMP-SMX), and retroviral therapy or prophylaxis, are also at increased risk dapsone are mainstays of PCP treatment and prophylaxis. for PCP (2). PCP may also develop in other immunosup- While prophylaxis has reduced the incidence of PCP, its pressed populations, such as cancer patients and transplant use has raised concerns about development of resistant organisms. The inability to culture human Pneumocystis, recipients. Furthermore, PCP remains a leading cause of Pneumocystis jirovecii, in a standardized culture system death among critically ill patients, despite advances in prevents routine susceptibility testing and detection of drug treatment and management (3). resistance. In other microorganisms, sulfa drug resistance The first-line treatment and prophylaxis regimen for has resulted from specific point mutations in the dihy- PCP is trimethoprim-sulfamethoxazole (TMP-SMX) (4). dropteroate synthase (DHPS) gene. Similar mutations While prophylaxis has been shown to reduce the incidence have been observed in P. jirovecii. Studies have consistent- of PCP, the widespread and long-term use of TMP-SMX in ly demonstrated a significant association between the use HIV patients has raised concerns regarding the develop- of sulfa drugs for PCP prophylaxis and DHPS gene muta- ment of resistant organisms. Even short-term exposure to tions. -
A Screening-Based Approach to Circumvent Tumor Microenvironment
JBXXXX10.1177/1087057113501081Journal of Biomolecular ScreeningSingh et al. 501081research-article2013 Original Research Journal of Biomolecular Screening 2014, Vol 19(1) 158 –167 A Screening-Based Approach to © 2013 Society for Laboratory Automation and Screening DOI: 10.1177/1087057113501081 Circumvent Tumor Microenvironment- jbx.sagepub.com Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia Harpreet Singh1,2, Anang A. Shelat3, Amandeep Singh4, Nidal Boulos1, Richard T. Williams1,2*, and R. Kiplin Guy2,3 Abstract Signaling by the BCR-ABL fusion kinase drives Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myelogenous leukemia (CML). Despite their clinical activity in many patients with CML, the BCR-ABL kinase inhibitors (BCR-ABL-KIs) imatinib, dasatinib, and nilotinib provide only transient leukemia reduction in patients with Ph+ ALL. While host-derived growth factors in the leukemia microenvironment have been invoked to explain this drug resistance, their relative contribution remains uncertain. Using genetically defined murine Ph+ ALL cells, we identified interleukin 7 (IL-7) as the dominant host factor that attenuates response to BCR-ABL-KIs. To identify potential combination drugs that could overcome this IL-7–dependent BCR-ABL-KI–resistant phenotype, we screened a small-molecule library including Food and Drug Administration–approved drugs. Among the validated hits, the well-tolerated antimalarial drug dihydroartemisinin (DHA) displayed potent activity in vitro and modest in vivo monotherapy activity against engineered murine BCR-ABL-KI–resistant Ph+ ALL. Strikingly, cotreatment with DHA and dasatinib in vivo strongly reduced primary leukemia burden and improved long-term survival in a murine model that faithfully captures the BCR-ABL-KI–resistant phenotype of human Ph+ ALL. -
Pharmacogenetic Testing: a Tool for Personalized Drug Therapy Optimization
pharmaceutics Review Pharmacogenetic Testing: A Tool for Personalized Drug Therapy Optimization Kristina A. Malsagova 1,* , Tatyana V. Butkova 1 , Arthur T. Kopylov 1 , Alexander A. Izotov 1, Natalia V. Potoldykova 2, Dmitry V. Enikeev 2, Vagarshak Grigoryan 2, Alexander Tarasov 3, Alexander A. Stepanov 1 and Anna L. Kaysheva 1 1 Biobanking Group, Branch of Institute of Biomedical Chemistry “Scientific and Education Center”, 109028 Moscow, Russia; [email protected] (T.V.B.); [email protected] (A.T.K.); [email protected] (A.A.I.); [email protected] (A.A.S.); [email protected] (A.L.K.) 2 Institute of Urology and Reproductive Health, Sechenov University, 119992 Moscow, Russia; [email protected] (N.V.P.); [email protected] (D.V.E.); [email protected] (V.G.) 3 Institute of Linguistics and Intercultural Communication, Sechenov University, 119992 Moscow, Russia; [email protected] * Correspondence: [email protected]; Tel.: +7-499-764-9878 Received: 2 November 2020; Accepted: 17 December 2020; Published: 19 December 2020 Abstract: Pharmacogenomics is a study of how the genome background is associated with drug resistance and how therapy strategy can be modified for a certain person to achieve benefit. The pharmacogenomics (PGx) testing becomes of great opportunity for physicians to make the proper decision regarding each non-trivial patient that does not respond to therapy. Although pharmacogenomics has become of growing interest to the healthcare market during the past five to ten years the exact mechanisms linking the genetic polymorphisms and observable responses to drug therapy are not always clear. Therefore, the success of PGx testing depends on the physician’s ability to understand the obtained results in a standardized way for each particular patient. -
Plague Plague
Disease Planning Guide - Plague Mass Post Exposure Prophylaxis I. Disease-specific guidance: The following guide should only be used in events where a plague epidemic has been identified, an Emergency Use Authorization from the Food and Drug Administration has been issued and a state and local emergency declaration has been issued by the proper authorities. Model Standing Order – Pg 1 Clients will arrive at dispensing sites with a voucher indicating which medication, if any, they should receive. Specific guidance related to dispensing is shown in red . Model Standing Order – Pg 2 Clients that present this voucher will not receive medication for the individual named on the form. Dispensers may collect “Do Not Dispense Medication” vouchers for records purposes. Model Standing Order – Pg 3 II. PERSONS FOR WHOM PROPHYLAXIS MAY BE ORDERED Persons who have a confirmed or suspect exposure to Yersinia pestis, the causative agent of plague, as determined by the local or State Health Officer. Table 1: Recommended Post-Exposure Prophylaxis for Inhalational Plague Patient Category Therapy Recommendation Duration 10 days Adults Doxycycline , 100 mg PO BID or Ciprofloxacin , 500 mg PO BID 10 days Ciprofloxacin , 15 mg/kg PO BID, max 500 mg/dose or Doxycycline : >45 kg: 100 mg PO BID Children <45 kg: 2.2 mg/kg PO BID ***************************************** If susceptibility to penicillin has been confirmed: Amoxicillin : >20 kg: 500 mg PO TID <20 kg: 80 mg/kg/day PO divided TID 10 days Doxycycline , 100 mg PO BID or Pregnant women Ciprofloxacin , 500 mg PO BID ***************************************** If susceptibility to penicillin has been confirmed: Amoxicillin 500 mg PO TID 10 days Immunocompromised Doxycycline , 100 mg PO BID or Ciprofloxacin , 500 mg PO BID Adapted from: Working Group on Civilian Biodefense.